In:
Cancer, Wiley, Vol. 122, No. 14 ( 2016-07-15), p. 2206-2215
Kurzfassung:
Population‐based studies of glioblastoma are scarce and traditionally have suffered from methodological limitations. In the current study, the authors demonstrate that, on a population level, the overall survival of patients with glioblastoma diagnosed in the Canton of Zurich in Switzerland has markedly improved from the pre‐temozolomide to the temozolomide era. Age, Karnofsky performance score, extent of tumor resection, first‐line treatment regimens, and, as demonstrated for the first time, MGMT promoter methylation status as well as isocitrate dehydrogenase 1 R132H mutation status are associated with survival today.
Materialart:
Online-Ressource
ISSN:
0008-543X
,
1097-0142
DOI:
10.1002/cncr.v122.14
Sprache:
Englisch
Verlag:
Wiley
Publikationsdatum:
2016
ZDB Id:
1479932-7
ZDB Id:
2599218-1
ZDB Id:
2594979-2
ZDB Id:
1429-1
